Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr. Ruchi Girotra

Dr. Ruchi Girotra

President Specialty Certified Medical Assistant,

Title: Prevalence of multi-drug resistant tuberculosis and implementation of infection prevention steps in a tertiary care hospital in south Asia for M.D.R tuberculosis

Biography

Biography: Dr. Ruchi Girotra

Abstract

Multi Drug Resistance (MDR) in Tuberculosis (TB) is a Global threat especially in Immunocompromised patients with India and China carrying the greatest estimated burden of Multi Drug Tuberculosis (MDR), Multidrug-resistant (MDR) tuberculosis is defined as disease caused by strains of Mycobacterium tuberculosis that are at least resistant to treatment with Isoniazid and Rifampicin.1

WHO ‘s updated policy document continues to strongly advise that Xpert MTB/RIF be used as the initial diagnostic test in both adults and children who are at risk of MDR-TB or HIV-associated TB, and that these two groups should be prioritized for testing with Xpert MTB/RIF when resources are limited.  2 We Used Xpert MTB /RIF system in our Hospital to predict prevalence of MDR Pulmonary TB in at risk population and thereby suggest Infection Prevention measures to prevent the spread. The case Finding for Clinical tuberculosis was based  on clinical history criteria defined according to  WHO’s Guidelines for the Programmatic Management of Drug-resistant TB .3 A total of 100 sputum specimens of patients >18 years of age and suspected of MDR pulmonary TB were followed over a period of 6 months. Average age of patients was 37 years and 52 specimens tested positive for Pulmonary TB and rifampicin resistance was detected in 49% of positive cases indicating high prevalence of rifampicin resistance and thereby suggesting Multi Drug Resistance. Rifampicin resistance is a reliable proxy for MDR-TB in patient groups in many countries (4-6) .Based on the findings, the Infection Prevention department suggested the following infection prevention steps in Chest and Tuberculosis department of the Hospital in order to prevent TB exposure to staff and patients, and (ii) to reduce the spread of infection by ensuring rapid diagnosis and treatment.

1 Screening of TB Suspects or patients on TB Medications.

2. Education of Patients.

3. Separation of TB Suspects from other patients.

4. Triaging.

5. Regular Training programs.

6. Use of Respirators  (N-95) were promoted in  bronchoscopy or specialized treatment centers.

7. Implementation of Environmental measures.

This Study emphasizes the need for methods for rapid diagnosis of MDR Tuberculosis like Xpert MTB/RIF the results of which are helpful in  rapid and effective implementation of Infection prevention measures in resource limited countries to control the spread .